AmbioPharm Provides an Update on Shanghai Campus Expansion and Resumption of Customer Visits

  • AmbioPharm has peptide manufacturing capacity and experience in 100kg batches and beyond
  • AmbioPharm Shanghai Campus resuming onsite visits

Shanghai AmbioPharm Campus (Photo: Business Wire)

NORTH AUGUSTA, S.C. & SHANGHAI--()--AmbioPharm Inc., a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial peptide production. The latest addition to the AmbioPharm Shanghai campus1,2 brings a total of approximately 380,550 square feet of manufacturing and administrative space. The ongoing expansion to the Shanghai campus includes reactors as large as 5,000 liters and additional purification suites, including a new 60cm HPLC column. A hydrogenation facility for Liquid Phase Peptide Synthesis (LPPS) was also recently completed and fully qualified.

Expansion highlights include:

  • Process optimization suites
  • Purification suite expansion, including 60cm HPLC column
  • New precipitation suite
  • cGMP pilot synthesis suite
  • Hydrogenation facility for LPPS
  • 6 manufacturing lines with 71 reactors with plans to add 7 additional lines for large scale
  • Solvent recycling

An additional building is currently underway that features state-of-the-art 3,000L SPPS and 3,000L LPPS systems and is expected to come online as early as Q4, 2023. Furthermore, we have resumed in-person site visits in our Shanghai campus. “Now that the COVID restrictions have been eased in China in late 2022, we welcome onsite customer visits and audits of our Shanghai campus,” says Brant Zell, Sr. VP of Quality.

With a commitment to continued growth in both equipment and technology, AmbioPharm is ready to meet the peptide API needs of customers. Using our expanding capacity, we have already manufactured several products at > 100kg batch sizes and our scientists are experts in both small and large capacity peptide production.

About AmbioPharm Inc.:

AmbioPharm is a leading and innovation-driven company specializing in the development and manufacture of peptides and peptide-related products. With a comprehensive range of services and scales, AmbioPharm produces custom products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. Headquartered in the United States of America and with campuses in both the USA and Asia, AmbioPharm operates internationally with extensive experience and expertise. Further information is available at:





Mark DaFonseca, EVP, Sales & Global Business Development


Mark DaFonseca, EVP, Sales & Global Business Development